243 related articles for article (PubMed ID: 12461014)
1. In vitro activity of quinupristin/dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci.
John MA; Pletch C; Hussain Z
J Antimicrob Chemother; 2002 Dec; 50(6):933-8. PubMed ID: 12461014
[TBL] [Abstract][Full Text] [Related]
2. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
Kenny GE; Cartwright FD
Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of telithromycin, quinupristin/dalfopristin, linezolid and comparator antimicrobial agents against Staphylococcus aureus clinical isolates.
Millán L; Cerdá P; Rubio MC; Goñi P; Canales M; Capilla S; Oca M; Gómez-Lus R
J Chemother; 2004 Jun; 16(3):230-7. PubMed ID: 15330317
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of telithromycin and quinupristin/dalfopristin against methicillin-resistant coagulase-negative staphylococci with defined resistance genotypes.
Novotná G; Spízek J; Janata J
Folia Microbiol (Praha); 2007; 52(6):593-9. PubMed ID: 18450221
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of antimicrobial agents against oxacillin resistant staphylococci with special reference to Staphylococcus haemolyticus.
Chaudhury A; Kumar AG
Indian J Med Microbiol; 2007 Jan; 25(1):50-2. PubMed ID: 17377353
[TBL] [Abstract][Full Text] [Related]
7. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones.
Bråbäck M; Riesbeck K; Forsgren A
Antimicrob Agents Chemother; 2002 Apr; 46(4):1114-6. PubMed ID: 11897601
[TBL] [Abstract][Full Text] [Related]
8. In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Harper T; Miller D; Flynn HW
Ophthalmology; 2007 May; 114(5):871-5. PubMed ID: 17383732
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility to quinupristin-dalfopristin and linezolid in 839 clinical isolates of Gram-positive cocci from Norway.
Simonsen GS; Bergh K; Bevanger L; Digranes A; Gaustad P; Melby KK; Høiby EA
Scand J Infect Dis; 2004; 36(4):254-8. PubMed ID: 15198180
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of telithromycin, linezolid, and quinupristin-dalfopristin against Streptococcus pneumoniae with macrolide resistance due to ribosomal mutations.
Farrell DJ; Morrissey I; Bakker S; Buckridge S; Felmingham D
Antimicrob Agents Chemother; 2004 Aug; 48(8):3169-71. PubMed ID: 15273142
[TBL] [Abstract][Full Text] [Related]
12. Activities of clindamycin, synercid, telithromycin, linezolid, and mupirocin against Gram-positive coccal strains resistant to erythromycin in Korea.
Kwon AR; Yoon EJ; Yoon JM; Kim H; Shim MJ; Choi EC
Arch Pharm Res; 2007 Jul; 30(7):840-3. PubMed ID: 17703735
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci.
von Eiff C; Peters G
J Antimicrob Chemother; 1999 Apr; 43(4):569-73. PubMed ID: 10350389
[TBL] [Abstract][Full Text] [Related]
15. Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci.
Betriu C; Redondo M; Boloix A; Gómez M; Culebras E; Picazo JJ
J Antimicrob Chemother; 2001 Dec; 48(6):911-3. PubMed ID: 11733478
[TBL] [Abstract][Full Text] [Related]
16. Patterns of phenotypic resistance to the macrolide-lincosamide-ketolide-streptogramin group of antibiotics in staphylococci.
Hamilton-Miller JM; Shah S
J Antimicrob Chemother; 2000 Dec; 46(6):941-9. PubMed ID: 11102413
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of newer antibiotics against Corynebacterium jeikeium, Corynebacterium amycolatum and Corynebacterium urealyticum.
Sánchez Hernández J; Mora Peris B; Yagüe Guirao G; Gutiérrez Zufiaurre N; Muñoz Bellido JL; Segovia Hernández M; García Rodríguez JA
Int J Antimicrob Agents; 2003 Nov; 22(5):492-6. PubMed ID: 14602367
[TBL] [Abstract][Full Text] [Related]
18. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
